Skip to main content
SpringerLink
Log in

Cross-resistance and cross-susceptibility between fluoroquinolone agents

  • Article
  • Published:
European Journal of Clinical Microbiology and Infectious Diseases Aims and scope Submit manuscript

Abstract

The results of broth microdilution susceptibility tests with 750 bacterial isolates were used to directly compare six different fluoroquinolone antibioties (ciprofloxacin, enoxacin, fleroxacin, lomefloxacin, ofloxacin and temafloxacin). Against enteric bacilli, enoxacin and lomefloxacin were similar in their spectra of activity but they differed from the other drugs tested. Against the non-enteric gram-negative bacilli, ciprofloxacin differed from enoxacin and lomefloxacin: fleroxacin, ofloxacin and temafloxacin were nearly identical in their activity. For routine susceptibility tests, ofloxacin and fleroxacin were similar in activity and either drug could be used as a class representative for predicting susceptibility to the other fluoroquinolone agents. Occasionally, strains that are resistant to the class representative may be susceptible to other members of the fluoroquinolone class, but those that are susceptible to the class representative are rarely resistant to the other compounds.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ronald AR, Turck M, Petersdorf RG A critical evaluation of nalidixic acid in urinary tract infections. New England Journal of Medicine 1966, 275: 1081–1089.

    PubMed  Google Scholar 

  2. Duckworth GJ, Williams JD Frequency of appearance of resistant variants to norfloxacin and nalidixic acid. Journal of Antimicrobial Chemotherapy 1984, 13, Supplement B: 33–38.

    PubMed  Google Scholar 

  3. Fernandes PB, Hanson CW, Stamm JM, Vojtko C, Shipkowitz NL, St Martin E The frequency of in vitro resistance development to fluoroquinolones and the use of a murine pyelonephritis model to demonstrate selection of resistance in vivo. Journal of Antimicrobial Chemotherapy 1987, 19: 449–465.

    PubMed  Google Scholar 

  4. Limb DI, Dabbs DJW, Spenser RC In vitro selection of bacteria resistant to the 4-quinolone agents. Journal of Antimicrobial Chemotherapy 1987, 19: 65–71.

    PubMed  Google Scholar 

  5. Piffaretti JC, Demarta A, Leidi-Bulla L, Peduzzi R In vitro emergence ofEscherichia coli andPseudomonas aeruginosa strains resistant to norfloxacin and nalidixic acid. European Journal of Clinical Microbiology 1983, 2: 600–601.

    PubMed  Google Scholar 

  6. Tenney JH, Maak RW, Chippendale GR Rapid selection of organisms with increasing resistance on subinhibitory concentrations of norfloxacin in agar. Antimicrobial Agents and Chemotherapy 1983, 23: 188–189.

    PubMed  Google Scholar 

  7. Verschraegen G, Claeys G, Van den Abeele AM Comparative in vitro activity of the new quinolone fleroxacin (Ro 23-6240). European Journal of Clinical Microbiology and Infectious Disease 1988, 7: 63–66.

    Google Scholar 

  8. Barry AL, Gardiner RV, Packer RR Resistance to ten different fluoroquinolone antibiotics following in vitro exposures to nalidixic acid. Diagnostic Microbiology and Infectious Disease 1987, 6: 77–79.

    PubMed  Google Scholar 

  9. Barry AL, Jones RN Cross-resistance among cinoxacin, ciprofloxacin, DJ-6783, enoxacin, nalidixic acid, norfloxacin, and oxolinic acid after in vitro selection of resistant populations. Antimicrobial Agents and Chemotherapy 1984, 25: 775–777.

    PubMed  Google Scholar 

  10. National Committee for Clinical Laboratory Standards Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A2. NCCLS, Villanova, PA, 1990.

    Google Scholar 

  11. Phillips I, King A, Shannon K In vitro properties of the quinolones. In: Andriole VT (ed): The quinolones. Academic Press, San Diego, CA, 1988, p. 83–117.

    Google Scholar 

  12. Shalit I, Berger SA, Gorea A, Frimerman H Widespread quinolone resistance and methicillin-resistantStaphylococcus aureus isolates in a general hospital. Antimicrobial Agents and Chemotherapy 1989, 33: 593–594.

    PubMed  Google Scholar 

  13. Barry AL, Draper DL, Wong MK Aerobic and anaerobic susceptibility tests with three tetracyclines: reassessment of the “class concept” of disk testing. American Journal of Clinical Pathology 1978, 70: 821–825.

    PubMed  Google Scholar 

  14. Barry AL, Jones RN Cross-susceptibility and absence of cross-resistance to cefotetan and cefoxitin. Journal of Clinical Microbiology 1987, 25: 1570–1571.

    PubMed  Google Scholar 

  15. Barry AL, Thornsberry C, Jones RN, Gavan TL In vitro activity of mezlocillin and azlocillin, compared with that of four other penicillins and two aminoglycosides. Cleveland Clinic Quarterly 1980, 47: 311–319.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Clinical Microbiology Institute, PO Box 947, 97062, Tualatin, Oregon, USA

    A. L. Barry

  2. St. Vincent Hospital and Medical Center, 97225, Portland, Oregon, USA

    P. C. Fuchs

Authors
  1. A. L. Barry
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. C. Fuchs
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Barry, A.L., Fuchs, P.C. Cross-resistance and cross-susceptibility between fluoroquinolone agents. Eur. J. Clin. Microbiol. Infect. Dis. 10, 1013–1018 (1991). https://doi.org/10.1007/BF01984922

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01984922

Keywords

Search

Navigation